Travere Therapeutics (TVTX) Non Operating Income (2013 - 2026)
Travere Therapeutics' (TVTX) quarterly Non Operating Income came in at $193000.0 in Q1 2026, down 87.02% YoY from $1.5 million in Q1 2025, and down 98.3% on a QoQ basis from $11.4 million in Q4 2025.
Travere Therapeutics (TVTX) Non Operating Income (2013 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 14 years of Non Operating Income data on file, last reported at $193000.0 in Q1 2026.
- Quarterly Non Operating Income fell 87.02% year-over-year to $193000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 818.59% YoY) and the FY2025 annual result came in at $13.6 million, up 308.53% from the prior year.
- Non Operating Income eased to $193000.0 in Q1 2026, from $11.4 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $11.4 million in Q4 2025 to a low of -$9.8 million in Q1 2022.
- A 5-year average of $949411.8 and a median of $883000.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income slumped 189.4% — and 2025, when it surged 2762.22%.
- Tracing TVTX's Non Operating Income over 5 years: stood at $1.1 million in 2022, then jumped by 405.31% to $5.7 million in 2023, then sank by 93.04% to $397000.0 in 2024, then surged by 2762.22% to $11.4 million in 2025, then sank by 98.3% to $193000.0 in 2026.
- The last three Non Operating Income figures came in at $193000.0 (Q1 2026), $11.4 million (Q4 2025), and $783000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | -38.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.96 Mn |
| Mar 31, 2026 | 193,000.00 |
| Dec 31, 2025 | 11.36 Mn |
| Sep 30, 2025 | 783,000.00 |
| Jun 30, 2025 | -85,000.00 |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 397,000.00 |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Mar 31, 2024 | 3.47 Mn |
| Dec 31, 2023 | 5.71 Mn |
| Sep 30, 2023 | 3.36 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 883,000.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | -1.31 Mn |
| Jun 30, 2022 | -2.97 Mn |
| Mar 31, 2022 | -9.79 Mn |
| Dec 31, 2021 | -6.14 Mn |
| Sep 30, 2021 | -4.90 Mn |